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The availability of the Antiretroviral (ARV) generic formu-
lations since 2000 has increased dramatically the demand
to access care and ARV drugs in the developping countries.
Most of the subsaharian African and Asian countries
which reported an epidemic have started to benefit from
the various international supports.
Although there is a global consensus among the devel-
opped countries to make the ARV access easier for the
developping countries, the frequent lack of sustained
structures and well trained medical teams in addition to
the lack of facilities are at high risk of emergence of resist-
ant viral strains and compromission of the expected ben-
efits.
In Burma the ARV implementation and scaling up have
considered the possible mechanisms to decline the risk of
emergence of a rapid resistance to the ARVs.
Burma one of the poorest country of the world has 50 mil-
lions of inhabitants. The UNAIDS estimates that the prev-
alence of the HIV infection is between 2 and 3% of the
global population. It is the third country of the South East
Asian region (SEAR) in term of prevalence after Cambodia
and Thailand.
The mix of high level of poverty, low awareness, poor
health care, low political involvement, and total lack of
governmental funds dedicated to this infection led the few
skills to collaborate closely to set up a comprehensive pro-
gramme aimed at fighting HIV/AIDS in this country pre-
vented from accessing to most of international supports
because of the political sanctions.
The french government signed an agreement in 1996 with
the Burma's medical school to traine MDs in France for
HIV/AIDS. 6 out of them have already been trained. The
french oil company Total joined this programme in 2004
to provide medical scholarships. The 7th MD that the
Total company has supported is the first Burma's peadia-
trician trained especially for HIV/AIDS in children in
Paris. After their return, these medical leaders have been
posted in the 2 referral HIV/AIDS departments imple-
mented in the 2 main cities (yangon and Mandalay) with
the tecbnical support of WHO.
The Yadana company operated by Total in Burma has pro-
vided the financial support for the purchase of the ARVs
which are ordered by WHO to avoid any custom fees, to
ensure a regular supply and avoid shortages.
The recipient for the Total funds is the Union: an Int'NGO
well implemented in numerous developping countries in
charge of Tuberculosis (TB). TB is the most frequent infec-
tion encountered in HIVpatients and occurs at any time of
the disease progression. This choice is a major contribu-
tion, since it has provided for the first time the opportu-
nity to detect and treat HIV patients at an earlier disease
stage. Up to now the government allowed to perform the
HIV testing only in patients with evident clinical diagnosis
of AIDS. The benefit of the ARV treatment started at a late
disease stage is very limited compared to the one when
started at an earlier stage. This earlier HIV testing possibil-
ity is the first step toward the voluntary testing in asymp-
tomatic people who just whish to know their own status.
The HIV testing center has been implemented for the first
time outside the walls of the AIDS center in the TB center.
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The test kits are provided by UNAIDS. It is the first time
that the test is done anonymously in in a public place.
The setting for the programme is the General Hospital in
Mandlay, the second city of the country. All the criteria
required to start the programme are met at this place. The
patients are monitored by the MDs trained in France. The
organization of the management of the patients has been
set up by the Union which delivers the drugs to the hospi-
tal, supports the cost of the laboratories facilities as well as
the cost of the management of the opportunistic infec-
tions. 2MDs from this IntNGO specialized in TB and in
HIV in the developping countries are responsible for this
program.
This is the first free access to the ARVs and to the care for
HIV infection in a public hospital in this country.
The anonymous testing (approved by the government),
the monitoring of the patients by the well trained MDs,
the management of the programme performed by the
MDs of the Union, the funds provided by Yadana com-
pany, and the support of WHO is an exemple of a global
commitment.
One major objective of the programme is to limit the
resistant viral strains which should start in Burma in
patients followed up in the private sector where the drugs
prescribed : monotherapy, bitherapy or tripletherapy are
related to the shortages and supplies, to the variable med-
ical knowledge and to the patient's financial resources.
The success of this programme should drive the few thou-
sands patients followed up in the private sector to the
public sector providing since recently confidentiality and
free access to the ARV treatment and care.
This programme is in the frame of the WHO 3 × 5 initia-
tive and contributes to the sustained development.
This rare example of a synergistic and close collaboration
between different structures should help to find addi-
tional funds to join the programme and expand it to other
hospitals in Burma.Page 2 of 2
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